Influence of risk factors on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen in two randomized controlled trials

被引:44
作者
Hawkey, CJ [1 ]
Laine, L
Harper, SE
Quan, HUI
Bolognese, JA
Mortensen, E
机构
[1] Univ Hosp, Queens Med Ctr, Div Gastroenterol, Nottingham NG7 2UH, England
[2] Univ So Calif, Los Angeles, CA 90089 USA
[3] Merck Res Labs, West Point, PA USA
[4] Merck & Co Inc, Whitehouse Stn, NJ USA
关键词
D O I
10.1046/j.1365-2036.2001.01007.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background: Highly selective inhibitors of the inducible cyclooxygenase-2 enzyme (coxibs) have been associated with less gastrotoxicity than nonselective NSAIDs in clinical studies. Aim: To evaluate the influence of risk factors for NSAID-induced gastrotoxicity on endoscopic and clinical ulcers in patients taking rofecoxib or ibuprofen. Methods: We analysed pooled data from two identical double-blind, randomized, 12-week endoscopy studies which compared the gastroduodenal toxicity of placebo (n=371), rofecoxib 25 mg (n=390), rofecoxib 50 mg (n=379), and ibuprofen 2400 mg daily (n=376) in patients with osteoarthritis. The potential risk factors evaluated were: age (<65, <greater than or equal to>65 years), sex, race (white, nonwhite), Helicobacter pylori status, presence of gastroduodenal erosions at baseline, a history of upper gastrointestinal disease, prior NSAID use within 30 days of study entry, and smoking. We also evaluated these factors for possible association with the development of clinically-evident gastrointestinal perforations, ulcers or bleeds over 12 weeks. Results: Across all treatment groups, the likelihood of detecting endoscopic ulcers, or of clinical presentation with a bleed, over 12 weeks was increased approximately 4-5-fold in patients with previous upper gastrointestinal disease (relative risk [95% confidence interval] of 4.2 [2.5, 7.1] for endoscopic ulcers; 3.8 [1.4, 10.6] for bleeds), or those with gastroduodenal erosions at baseline endoscopy (relative risk of 4.4 [2.6, 7.5] for endoscopic ulcers; 5.0 [1.9, 13.5] for bleeds). H. pylori infection did not increase the risk of endoscopic ulcers or bleeds (relative risk of 1.1 [0.8, 1.6] for endoscopic ulcers; 0.3 [0.1, 0.9] for bleeds). The risk factor subgroup effects were constant across all treatment groups, and the significantly higher incidence of ulcers with ibuprofen as compared to rofecoxib, and placebo was maintained in all risk factor subgroups. Conclusions: Gastroduodenal erosions at baseline and a clinical history of upper gastrointestinal disease, but not H. pylori colonization, increased the risk for endoscopically-detected ulcers and clinical bleeds. Rofecoxib did not magnify the risk in any of the patient subgroups studied.
引用
收藏
页码:1593 / 1601
页数:9
相关论文
共 25 条
  • [1] Cannon G, 1998, ARTHRITIS RHEUM, V41, pS196
  • [2] Chan CC, 1999, J PHARMACOL EXP THER, V290, P551
  • [3] CYCLOOXYGENASE-1 AND CYCLOOXYGENASE-2 EXPRESSION IN RHEUMATOID SYNOVIAL TISSUES - EFFECTS OF INTERLEUKIN-1-BETA, PHORBOL ESTER, AND CORTICOSTEROIDS
    CROFFORD, LJ
    WILDER, RL
    RISTIMAKI, AP
    SANO, H
    REMMERS, EF
    EPPS, HR
    HLA, T
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1994, 93 (03) : 1095 - 1101
  • [4] Cryer Byron, 1998, American Journal of Medicine, V105, p20S, DOI 10.1016/S0002-9343(98)00071-0
  • [5] Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model
    Ehrich, EW
    Dallob, A
    De Lepeleire, I
    Van Hecken, A
    Riendeau, D
    Yuan, WY
    Porras, A
    Wittreich, J
    Seibold, JR
    De Schepper, P
    Mehlisch, DR
    Gertz, BJ
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1999, 65 (03) : 336 - 347
  • [6] FU JY, 1990, J BIOL CHEM, V265, P16737
  • [7] RISK FOR SERIOUS GASTROINTESTINAL COMPLICATIONS RELATED TO USE OF NONSTEROIDAL ANTIINFLAMMATORY DRUGS - A METAANALYSIS
    GABRIEL, SE
    JAAKKIMAINEN, L
    BOMBARDIER, C
    [J]. ANNALS OF INTERNAL MEDICINE, 1991, 115 (10) : 787 - 796
  • [8] SIMULTANEOUS VISUALIZATION OF HELICOBACTER-PYLORI AND GASTRIC MORPHOLOGY - A NEW STAIN
    GENTA, RM
    ROBASON, GO
    GRAHAM, DY
    [J]. HUMAN PATHOLOGY, 1994, 25 (03) : 221 - 226
  • [9] COMPARISON OF BIOPSY SITES FOR THE HISTOPATHOLOGIC DIAGNOSIS OF HELICOBACTER-PYLORI - A TOPOGRAPHIC STUDY OF HELICOBACTER-PYLORI DENSITY AND DISTRIBUTION
    GENTA, RM
    GRAHAM, DY
    [J]. GASTROINTESTINAL ENDOSCOPY, 1994, 40 (03) : 342 - 345
  • [10] NONSTEROIDAL ANTIINFLAMMATORY DRUG-USE AND INCREASED RISK FOR PEPTIC-ULCER DISEASE IN ELDERLY PERSONS
    GRIFFIN, MR
    PIPER, JM
    DAUGHERTY, JR
    SNOWDEN, M
    RAY, WA
    [J]. ANNALS OF INTERNAL MEDICINE, 1991, 114 (04) : 257 - 263